Q4 2026 Anthem Biosciences Ltd Earnings Call Transcript
Key Points
- Anthem Biosciences Ltd (NSE:ANTHEM) reported a strong financial performance for FY25-26, with consolidated revenue from operations reaching INR2,124 crore, marking an 18% growth over the previous year.
- The company's CRDMO business contributed significantly to revenue, delivering INR1,773 crore, which represents an 18% growth year-on-year.
- EBITDA for the year was INR990 crore, with margins of 43.4%, reflecting a 31% growth in absolute terms and a 420 basis point increase in margins.
- Anthem Biosciences Ltd (NSE:ANTHEM) maintained a healthy net cash position of INR1,375 crore as of March 31, 2026.
- The company is investing in technology and capacity expansion, including a significant project for Unit 4, which will more than double its current capacity, positioning it for future growth.
- The company faced challenges with destocking in FY26, although it expects this situation to improve with restocking in the future.
- There is uncertainty regarding the timing of commercialization for certain products, such as GLP-1, which could impact future revenue streams.
- Anthem Biosciences Ltd (NSE:ANTHEM) refrained from providing specific guidance for FY27 or FY28, creating some uncertainty about near-term financial performance.
- The company faces competition from peers in both domestic and international markets, particularly in areas like peptide manufacturing.
- There are potential risks related to geopolitical situations and inflationary pressures, which could impact the company's operations and profitability.
Ladies and gentlemen, good day and welcome to the Anthem Biosciences Q4 FY26 earnings conference call hosted by JM Financial Institutional Securities. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Amey Chalke from JM Financial Institutional Securities. Please go ahead.
Yeah, thanks, Alwick. Good morning, and warm welcome to all the participants on Anthem Biosciences 4Q and FY25 earnings call hosted by JM Financial.
Today on this call, we have with us from the management, Mr. Ajay Bhardwaj, Managing Director and Chief Executive Officer; and Mr. Gawir Baig, Chief Financial Officer.
I will now hand over the call to Mr. Ajay Bhardwaj for his opening remarks. Thank you, and over to you, sir.
()
Yeah, thank you, Amey. And thank you, everyone, for being
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
